Comparison Overview

Gilead Sciences

VS

Roche

Gilead Sciences

333 Lakeside Drive, Foster City, CA, US, 94404
Last Update: 2025-12-09
View Profile
Between 750 and 799
http://www.gilead.com

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 14,615
Subsidiaries: 10
12-month incidents
1
Known data breaches
1
Attack type number
2
View Profile

Roche

Grenzacherstrasse, None, Switzerland 🇨🇭 , None, CH, 4070
Last Update: 2025-12-09
Between 800 and 849
http://www.roche.com/

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 99,293
Subsidiaries: 51
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/gilead-sciences.jpeg
Gilead Sciences
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/roche.jpeg
Roche
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Gilead Sciences
100%
Compliance Rate
0/4 Standards Verified
Roche
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

Gilead Sciences has 49.25% more incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for Roche in 2025.

Incident History — Gilead Sciences (X = Date, Y = Severity)

Gilead Sciences cyber incidents detection timeline including parent company and subsidiaries

Incident History — Roche (X = Date, Y = Severity)

Roche cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/gilead-sciences.jpeg
Gilead Sciences
Incidents

Date Detected: 2/2025
Type:Breach
Attack Vector: Human Error (Mailing Error)
Blog: Blog

Date Detected: 05/2020
Type:Cyber Attack
Attack Vector: Phishing, Server Compromise
Blog: Blog
https://images.rankiteo.com/companyimages/roche.jpeg
Roche
Incidents

No Incident

FAQ

Roche company demonstrates a stronger AI Cybersecurity Score compared to Gilead Sciences company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Gilead Sciences company has historically faced a number of disclosed cyber incidents, whereas Roche company has not reported any.

In the current year, Gilead Sciences company has reported more cyber incidents than Roche company.

Neither Roche company nor Gilead Sciences company has reported experiencing a ransomware attack publicly.

Gilead Sciences company has disclosed at least one data breach, while the other Roche company has not reported such incidents publicly.

Gilead Sciences company has reported targeted cyberattacks, while Roche company has not reported such incidents publicly.

Neither Gilead Sciences company nor Roche company has reported experiencing or disclosing vulnerabilities publicly.

Neither Gilead Sciences nor Roche holds any compliance certifications.

Neither company holds any compliance certifications.

Roche company has more subsidiaries worldwide compared to Gilead Sciences company.

Roche company employs more people globally than Gilead Sciences company, reflecting its scale as a Biotechnology Research.

Neither Gilead Sciences nor Roche holds SOC 2 Type 1 certification.

Neither Gilead Sciences nor Roche holds SOC 2 Type 2 certification.

Neither Gilead Sciences nor Roche holds ISO 27001 certification.

Neither Gilead Sciences nor Roche holds PCI DSS certification.

Neither Gilead Sciences nor Roche holds HIPAA certification.

Neither Gilead Sciences nor Roche holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A weakness has been identified in itsourcecode Online Pet Shop Management System 1.0. This vulnerability affects unknown code of the file /pet1/addcnp.php. This manipulation of the argument cnpname causes sql injection. The attack can be initiated remotely. The exploit has been made available to the public and could be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A security flaw has been discovered in Tenda AX9 22.03.01.46. This affects the function image_check of the component httpd. The manipulation results in use of weak hash. It is possible to launch the attack remotely. A high complexity level is associated with this attack. It is indicated that the exploitability is difficult. The exploit has been released to the public and may be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 2.6
Severity: HIGH
AV:N/AC:H/Au:N/C:N/I:P/A:N
cvss3
Base: 3.7
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A weakness has been identified in code-projects Student File Management System 1.0. This issue affects some unknown processing of the file /admin/update_student.php. This manipulation of the argument stud_id causes sql injection. The attack is possible to be carried out remotely. The exploit has been made available to the public and could be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A security flaw has been discovered in code-projects Student File Management System 1.0. This vulnerability affects unknown code of the file /admin/save_user.php. The manipulation of the argument firstname results in sql injection. The attack can be executed remotely. The exploit has been released to the public and may be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A vulnerability was identified in code-projects Student File Management System 1.0. This affects an unknown part of the file /admin/update_user.php. The manipulation of the argument user_id leads to sql injection. Remote exploitation of the attack is possible. The exploit is publicly available and might be used.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References